STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about RHEP
Insiders, 180 days
+$52.3K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Regional Health Properties insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, REGIONAL HEALTH PROPERTIES, INC insiders bought a net $52.3K of stock across 21 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Nobody has filed for crossing 5%. That is a fact, not missing data.
RHEP planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Mr. Morrison
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$316.7K
$298.8K
$155.1K
-65%
n/a
2023
$291.8K
$266.0K
$236.6K
-55%
n/a
2022
$478.2K
$430.6K
$134.4K
-26%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $52.3K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$81.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RHEP
FY Dec 2025
$53.2M
FY Dec 2024
$18.3M
FY Dec 2023
$17.2M
FY Dec 2022
$35.9M
FY Dec 2021
$26.7M
Jun 2026
$24.4M
Mar 2026
$21.2M
Dec 2025
$20.8M
Sep 2025
$15.1M
Jun 2025
$10.1M
Mar 2025
$7.2M
Dec 2024
$5.7M
Sep 2024
$4.2M
At each fiscal year end
Single quarter
Net margin, TTM
+5.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RHEP
FY Dec 2025
+6.3%
FY Dec 2024
-17.5%
FY Dec 2023
-22.7%
FY Dec 2022
-19.1%
FY Dec 2021
-4.4%
Jun 2026
-3.2%
Mar 2026
-5.8%
Dec 2025
+13.0%
Sep 2025
+22.3%
Jun 2025
-14.4%
Mar 2025
-17.6%
Dec 2024
-10.0%
Sep 2024
-23.2%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$3.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RHEP
FY Dec 2025
-$3.1M
FY Dec 2024
$1.4M
FY Dec 2023
$2.8M
FY Dec 2022
-$3.9M
FY Dec 2021
$4.8M
Jun 2026
$889.0K
Mar 2026
-$1.3M
Dec 2025
-$1.5M
Sep 2025
-$2.1M
Jun 2025
$274.0K
Mar 2025
$171.0K
Dec 2024
$853.0K
Sep 2024
-$147.0K
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity RHEP
FY Dec 2025
115.05x
FY Dec 2024
n/a
FY Dec 2023
283.43x
FY Dec 2022
14.50x
FY Dec 2021
5.25x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
115.05x
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.07x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt RHEP
FY Dec 2025
-0.06x
FY Dec 2024
0.05x
FY Dec 2023
0.07x
FY Dec 2022
-0.07x
FY Dec 2021
0.09x
Jun 2026
-0.07x
Mar 2026
-0.09x
Dec 2025
-0.06x
Sep 2025
-0.00x
Jun 2025
0.03x
Mar 2025
0.03x
Dec 2024
0.05x
Sep 2024
0.02x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity RHEP
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
-199.3%
FY Dec 2022
-97.3%
FY Dec 2021
-11.0%
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RHEP
FY Dec 2025
+5.3%
FY Dec 2024
-5.2%
FY Dec 2023
-5.9%
FY Dec 2022
-7.9%
FY Dec 2021
-1.1%
Jun 2026
+6.4%
Mar 2026
+5.4%
Dec 2025
+5.3%
Sep 2025
+0.2%
Jun 2025
-7.0%
Mar 2025
-5.8%
Dec 2024
-5.2%
Sep 2024
-4.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital RHEP
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+4.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RHEP
FY Dec 2025
+4.0%
FY Dec 2024
+0.4%
FY Dec 2023
-2.1%
FY Dec 2022
-11.2%
FY Dec 2021
n/a
Jun 2026
+4.3%
Mar 2026
+3.4%
Dec 2025
+4.0%
Sep 2025
-1.9%
Jun 2025
-1.5%
Mar 2025
+0.3%
Dec 2024
+0.4%
Sep 2024
-0.6%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.64x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing RHEP
FY Dec 2025
2.56x
FY Dec 2024
n/a
FY Dec 2023
0.10x
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
0.67x
Mar 2026
1.08x
Dec 2025
2.56x
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$41.9M
market value at close 2026-10-26 on 2026-08-12 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value RHEP
FY Dec 2025
$42.2M
FY Dec 2024
$43.8M
FY Dec 2023
$55.3M
FY Dec 2022
$59.0M
FY Dec 2021
$55.8M
Jun 2026
$42.1M
Mar 2026
$43.5M
Dec 2025
$42.2M
Sep 2025
$53.9M
Jun 2025
$55.7M
Mar 2025
$56.0M
Dec 2024
$43.8M
Sep 2024
$54.3M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-95.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield RHEP
FY Dec 2025
-62.1%
FY Dec 2024
+48.1%
FY Dec 2023
+72.1%
FY Dec 2022
-66.0%
FY Dec 2021
+59.6%
Jun 2026
-91.2%
Mar 2026
-93.3%
Dec 2025
-62.1%
Sep 2025
-19.0%
Jun 2025
+22.9%
Mar 2025
+20.4%
Dec 2024
+48.1%
Sep 2024
+22.2%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing RHEP
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
RHEP ranks highest on growth (98th percentile) and profitability (76th), and lowest on financial health (7th), among Real Estate peers.
Profitability
76
Inputs
Return on equityaverage equity is zero or negative
Return on assets+6.4% · 91 pct, sector of 255
Return on invested capitalpre-tax loss, no effective tax rate to apply
Return on capital employed+4.3% · 61 pct, sector of 47
Financial health
7
Inputs
Debt to equityequity is zero or negative, the ratio has no meaning
Cash flow to debt-0.07x · 7 pct, sector of 215
Growth
98
Inputs
Revenue growth, YoY+189.9% · 98 pct, sector of 244
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
58
Inputs
Net Form 4 buying (codes P and S), 180d$52K · 66 pct, sector of 156
Insider buyers, 180d1 · 51 pct, sector of 158
Risk and compliance
46
Inputs
Short interest, % of float+0.2% · 91 pct, sector of 256
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+85.4% · 1 pct, sector of 212
2 not measured: Institutional and government, US patents
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RHEP filings, in plain words
Are Regional Health Properties insiders buying or selling RHEP?
In the 180 days to 2026-10-27, Regional Health Properties insiders were net buyers, a net $52.3K: $58.1K of purchases and $5.9K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Regional Health Properties insiders were net buyers of RHEP, a net $52.3K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.